Remove Physicians Remove Recruitment Remove Safety
article thumbnail

ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension

Legacy MEDSearch

In addition, pooled analysis results from the combined primary efficacy endpoint and safety data from RADIANCE SOLO, RADIANCE TRIO, and RADIANCE II were concurrently published in JAMA Cardiology. The study also achieved its primary safety composite outcome with no major adverse events observed. mmHg, compared to a reduction of -1.8

article thumbnail

FDA Awards HistoSonics Clearance of its First-of-a-Kind EdisonĀ® Histotripsy System

Legacy MEDSearch

Data pooled from both the US and European/UK trials were used to assess the clinical safety and efficacy of histotripsy in destroying targeted primary and secondary liver tumors. was achieved indicating that physicians can precisely target and destroy liver tissue and unresectable liver tumors.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software

Legacy MEDSearch

software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision. employs advanced computation and image registration to assist physicians in crucial steps of planning and assessing the ablation coverage of liver tumor. Techsomed Ltd.,

FDA 52
article thumbnail

CereVasc Announces FDA Approval of Second IDE Study of the eShuntĀ® System

Legacy MEDSearch

The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chairman of Neurosurgery, and Adel Malek, MD, PhD, Neurosurgeon and Chief of Neurovascular Surgery. Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry.

FDA 52
article thumbnail

Hip Innovation Technology Announces Initiation of FDA Approved Investigational Device Exemption Study

Legacy MEDSearch

The IDE Study is being conducted to determine the safety and effectiveness of the HIT Reverse HRS in Primary Total Hip Arthroplasty (THA). Safety will be assessed through the collection of device-related adverse events and patient quality of life metrics. Press Release by: Hip Innovation Technology.

FDA 98
article thumbnail

Rapid Medical Gains FDA Clearance for the Smallest & Only Adjustable Thrombectomy Device

Legacy MEDSearch

The ability to tailor each procedure can provide new safety levels for higher-risk thrombectomies. physicians finally have access to TIGERTRIEVER 13ā€™s unique capabilities to further benefit patients suffering from ischemic stroke.ā€. TIGERTRIEVER 17 and 21, COMANECI , and COLUMBUS /DRIVEWIRE are CE marked and FDA cleared.

Medical 52
article thumbnail

CereVasc Receives FDA IDE Approval to Expand its Clinical Study of Patients with Normal Pressure Hydrocephalus Utilizing the Generation 2 eShuntĀ® System

Legacy MEDSearch

to improve the usability of the system without compromising functionality or patient safety and are looking forward to its use in the study,” he continued. Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. Carl Heilman, M.D., and Adel Malek, M.D., About CereVasc, Inc.